These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27009330)

  • 1. Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia.
    Zheng Q; Cao J; Hamad N; Kim HJ; Moon JH; Sohn SK; Jung CW; Lipton JH; Kim DD
    J Transl Med; 2016 Mar; 14():82. PubMed ID: 27009330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.
    Annuar AA; Ankathil R; Mohd Yunus N; Husin A; Ab Rajab NS; Abdul Aziz AA; Ibrahim MI; Sulong S
    Asian Pac J Cancer Prev; 2021 Feb; 22(2):565-571. PubMed ID: 33639675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
    Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
    Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
    Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
    Bedewy AM; El-Maghraby SM
    Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.
    Jaruskova M; Curik N; Hercog R; Polivkova V; Motlova E; Benes V; Klamova H; Pecherkova P; Belohlavkova P; Vrbacky F; Machova Polakova K
    J Exp Clin Cancer Res; 2017 Apr; 36(1):55. PubMed ID: 28420426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
    Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
    J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.
    Koren-Michowitz M; Buzaglo Z; Ribakovsky E; Schwarz M; Pessach I; Shimoni A; Beider K; Amariglio N; le Coutre P; Nagler A
    Eur J Haematol; 2014 Apr; 92(4):283-8. PubMed ID: 24215657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Nucleotide Polymorphisms of FAS and FASL Genes and Risk of Idiopathic Aplastic Anemia.
    Rehman S; Saba N; Naz M; Ahmed P; Munir S; Sajjad S; Tabassum S; Naseem L
    Immunol Invest; 2018 Jul; 47(5):484-491. PubMed ID: 29611722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutathione S-transferase gene polymorphic sequence variations: Association with risk and response to Imatinib among Chronic Myeloid Leukemia patients of Kashmir.
    Baba SM; Shah ZA; Pandith AA; Geelani SA; Mir MM; Bhat JR; Gul A; Bhat GM
    Int J Lab Hematol; 2021 Oct; 43(5):1000-1008. PubMed ID: 33470551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia.
    Chhikara S; Sazawal S; Mishra P; Chaubey R; Mahapatra M; Saxena R
    Natl Med J India; 2015; 28(6):272-5. PubMed ID: 27294449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.
    Edathara PM; Gorre M; Kagita S; Vuree S; Cingeetham A; Nanchari SR; Meka PB; Annamaneni S; Digumarthi RR; Satti V
    Tumour Biol; 2016 Apr; 37(4):5475-84. PubMed ID: 26563376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
    Guru SA; Mir R; Bhat M; Najar I; Zuberi M; Sumi M; Masroor M; Gupta N; Saxena A
    Tumour Biol; 2017 Oct; 39(10):1010428317713857. PubMed ID: 29019285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.
    Cargnin S; Ravegnini G; Soverini S; Angelini S; Terrazzino S
    Pharmacol Res; 2018 May; 131():244-254. PubMed ID: 29427770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.
    Zheng Q; Wu H; Yu Q; Kim DH; Lipton JH; Angelini S; Soverini S; Vivona D; Takahashi N; Cao J
    Pharmacogenomics J; 2015 Apr; 15(2):127-34. PubMed ID: 25245580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
    Salimizand H; Amini S; Abdi M; Ghaderi B; Azadi NA
    Tumour Biol; 2016 Jan; 37(1):791-8. PubMed ID: 26250462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.